Soligenix, Inc. (SNGX)

Market Cap	6.97M
Revenue (ttm)	119,371
Net Income (ttm)	-8.27M
Shares Out	3.16M
EPS (ttm)	-4.98
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	61,147
Open	2.237
Previous Close	2.270
Day's Range	2.130 - 2.275
52-Week Range	1.830 - 14.880
Beta	2.03
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 21, 2025

About SNGX

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inf...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 15, 1987
• Employees: 15
• Stock Exchange: NASDAQ
• Ticker Symbol: SNGX
• Website: https://www.soligenix.com

Financial Performance

In 2024, Soligenix's revenue was $119,371, a decrease of -85.78% compared to the previous year's $839,359. Losses were -$8.27 million, 34.6% more than in 2023.